# KRAS vaccine (mRNA-5671)

*Last program update: May 6, 2021*

<table>
<thead>
<tr>
<th>Modality</th>
<th>ID #</th>
<th>Program Indication</th>
<th>Preclinical development</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3 and commercial</th>
<th>Moderna rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer vaccines</td>
<td>mRNA-4157</td>
<td>Personalized cancer Vaccine (PCV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50-50 global profit sharing with Merck</td>
</tr>
<tr>
<td></td>
<td>mRNA-5671/ Merck V941</td>
<td>KRAS vaccine, CRC, NSCLC, pancreatic cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50-50 global profit sharing with Merck</td>
</tr>
</tbody>
</table>

Phase 1 study ongoing; study run by Merck
Moderna’s mRNA vaccines elicit T cells required for curative cancer therapy
KRAS opportunity

*Mutation is present in >20% of human cancers*

- KRAS is a key regulator of cell proliferation and survival; mutations cause dysregulated cell proliferation
- One of the most frequently mutated oncogenes in human cancers
- Mutations found principally in pancreatic cancer, lung cancer, and colorectal cancer
- The four most prevalent KRAS mutations associated with these malignancies are G12D, G12V, G13D, and G12C (80% to 90% of KRAS mutations)

Patients whose tumors harbor KRAS mutations have worse outcomes
Anti-KRAS Tcell transfer shows human efficacy (Rosenberg, NIH)
**KRAS vaccine (mRNA-5671)**

*Preclinical data – Tcell responses after KRAS mRNA vaccination*

- **Species:** Mouse

**T cell response to restimulation with KRAS mutation 1 peptide in mouse model study**

**T cell response to restimulation with KRAS mutation 2 peptide in mouse model study**

CD8 T cell responses to KRAS antigens were greatly enhanced following vaccination with mRNA encoding KRAS mutations in pre-clinical studies.
KRAS vaccine (mRNA-5671)

Preclinical data – T cell responses after KRAS mRNA vaccination

Study Overview

• A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/Merck V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

• Selecting for HLA subtypes (HLA-A*1101 and/or HLA-C*0802) most likely to respond

Part 1:

mRNA-5671/V941 monotherapy
Advanced/metastatic solid tumors positive for KRAS mutation (G12D, G12V, G13D or G12C)

Part 1:

mRNA-5671/V941 combination with pembrolizumab
Advanced/metastatic solid tumors positive for KRAS mutation (G12D, G12V, G13D or G12C)

Part 2:

mRNA-5671/V941 combination with pembrolizumab
Advanced/metastatic NSCLC, non-MSI-H CRC or pancreatic adenocarcinoma, positive for KRAS mutation (G12D, G12V, G13D or G12C) and centrally confirmed HLA-A*1101 and/or HLA-C*0802 allele expression by HLA typing
Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new potential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.